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Abstract
We have reviewed the literature to form a bespoke regimen for daily oral prednisolone (DP) in GCA.
Initial DP in clinical trials is 40–60 mg daily, but relapse rates are 67–92%. Cumulative prednisolone
(CP) of 3.2 and 3.9 g (at 6 months) resulted in a relapse rate of 83 and 67%, respectively; and 3 and
3.9 g (at 12 months) resulted in 92 and 82% relapse, respectively. CP was 6.2–7.1 g in the first year.
Mean DP was 18.8 mg at 3 months and 6.6–7.4 mg at 12 months. The duration of treatment with pred-
nisolone for GCA was 22–26 months. The CP to achieve discontinuation was 6.5–12.1 g. Using these
data, the Norwich regimen starts DP at 1 mg/kg/day of lean body mass, discontinuing over 100 weeks.
For the average UK woman, initial DP is 45 mg daily, reaching 21 mg daily by 12 weeks and 6 mg daily
by 52 weeks. The CP for the average UK woman would be 6.5 g at 52 weeks and 7.4 g to
discontinuation.
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Introduction
GCA is the most common vasculitis in those over the
age of 50 years, with an annual incidence of 200/million
[1]. GCA was first described in 1890 by Sir Jonathan
Hutchinson [2]. Initial treatments included injection of pro-
caine hydrochloride [3], i.v. histamine [4], aureomycin [5]
and even surgical excision of the perceived culprit artery
[6]. Before the discovery and use of cortisone, there was
a high incidence of visual loss. In 1950, Bruce reviewed
84 cases and reported visual involvement in 34; 22 (26%)
had blindness, 13 cases (15%) of which were bilateral [7].
Loss of vision has catastrophic consequences on the
quality of life of an individual. Typically, in GCA, this hap-
pens without warning and is irreversible. One can go
from being completely independent to being completely
dependent for all activities of daily living if the diagnosis
is missed or the treatment inadequate. Anecdotal suc-
cess at reversal of visual involvement with anticoagulation
[8] has not been verified statistically [9]. The use of adre-
nal cortex hormones for managing the inflammatory bur-
den of this disease was first reported formally in 1957
[10], and since then CSs have been the only evidence-
based treatments until the steroid-sparing effect of MTX
was demonstrated in a meta-analysis [11], and tocilizu-
mab was shown to have disease-modifying properties
and steroid-sparing effects [12]. Prednisolone or predni-
sone has become the CS of choice for the long-term
management of this condition. No single dose or regimen
for their use has been validated. It is probably fair to say
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. The Norwich regimen is a bespoke regimen of daily oral prednisolone for managing GCA.
. Daily oral prednisolone dose may be 20 mg by 12 weeks and 5–7.5 mg by 52 weeks.
. Over 100 weeks, prednisolone can be discontinued with a cumulative dose of 164 mg/kg.
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that there are numerous different regimens in use, with
little scientific basis. We have formulated a regimen that
has become the standard for the management of GCA
across all hospital departments in the Norfolk and
Norwich University Hospital. In this review, we discuss
the evidence examined to form the regimen.
The role of i.v. methylprednisolone
Intravenous methylprednisolone (MP) has been used since
the 1990s at presentation, in an effort to preserve vision
[13]. Reports of improvement after i.v. MP, from loss of
light perception to baseline visual acuity, were extremely
encouraging [14]. However, there were contrary reports
about this strategy on the basis of anecdotal worsening
of vision despite the use of i.v. MP [15]. Foroozan et al.
[16] treated 32 consecutive biopsy-proven GCA patients
with anterior ischaemic optic neuropathy or central retinal
artery arterial occlusion with 1 g i.v. MP for 3 days. There
was some recovery in 13% of eyes, but all were left with
significant constriction of the visual field [16]. Likewise,
Danesh-Meyer et al. [17] treated 34 consecutive patients
and reported continuing deterioration in 27% of eyes in
spite of the high dose of i.v. MP. They found that irre-
spective of high-dose CSs, there remained a risk of visual
deterioration in the first 6 days [17]. The only randomized
controlled trial of i.v. MP vs placebo excluded patients
with visual involvement, and none of the patients in the
trial developed new vascular complications [18]. In our
centre, we do not regularly give i.v. MP to patients with
visual involvement but would consider it on a case-by-
case basis. Considering the small risk of high-impact
complications, such as gastric erosions, sepsis, other
infections, anaphylaxis and cardiac arrest, reported after
i.v. MP [19–21], this is a decision that requires careful
consideration in all individuals. Current EULAR recom-
mendations state that pulsed i.v. MP may be of benefit to
some patients who present early after the onset of visual
symptoms [22]. The current British recommendations
state that pulsed i.v. MP should be considered in evolving
visual loss or amaurosis fugax [23]. Practically, we admin-
ister i.v. MP for patients who present with central or
branch retinal artery occlusion or anterior ischaemic optic
neuropathy. Patients with diabetes mellitus, a history of
avascular necrosis, acid-peptic disease, previous history
of pancreatitis, psychiatric disorders, epilepsy, recent
myocardial infarction (in the previous 12 months), conges-
tive heart failure or a past history of thromboembolism are
considered to have relative contraindications to i.v. MP.
The starting dose of prednisolone
There is no agreement on the starting dose of oral pred-
nisolone, only that high-dose CSs must be commenced
as soon as the suspicion of GCA is raised [22]. The
often-quoted starting dose of oral prednisolone is 60 mg
daily. This anachronism is based on the first clinical trial
published in 1957, in which the starting dose of cortisone
was 300 mg daily [10], which is equivalent to prednisolone
60 mg daily. Clinical trials have used several different
doses in different ways. The starting dose has varied
from prednisolone 20 mg daily [24, 25] to 60 mg daily [12,
26–31]. Some studies have reported using a weight-
based starting dose of 0.7 mg/kg/day [32, 33]. The cur-
rent European recommendations suggest 1 mg/kg/day to
a maximum of 60 mg daily [22]. Universally, every author
has commented that their patients entered remission as
defined by amelioration of clinical signs and normalization
of inflammatory markers. Myles et al. [24] commented
that prednisolone 20 mg daily was sufficient to avoid vi-
sual complications. Proven et al. [31] published their ex-
perience from the Mayo Clinic, and although the median
starting dose was 60 mg daily, the lower end of the range
was 10 mg daily. It could be inferred that the practice of
giving higher doses of prednisolone is either a historical
aberration or it has value in preventing future relapses.
Evidence for the latter is discussed later.
In an ideal world, we would want to provide a tailored
CS regimen to individuals to fine-tune the risk of relapse
vs the risk of adverse effects of prednisolone. We could
consider various factors that might alter this risk–benefit
ratio: cranial vs extra-cranial disease, sex, body size,
co-morbidities, inflammatory markers etc. However, as it
happens, even when we are left to our own devices and
treat our patients depending on the changing clinical
scenario, we do not treat cranial and extra-cranial dis-
ease any differently [34]. De Boysson et al. [34] per-
formed a retrospective review of 80 patients (40 with
cranial GCA and 40 with further involvement of extracra-
nial large arteries). There was no difference between the
two groups in the initial median dose of prednisone or
overall duration of prednisolone therapy [34].
The pharmacokinetics of prednisolone is complicated
in humans. After single high doses, the pharmacokinet-
ics is predictable, with plasma protein-bound drug
showing dose-dependent clearance and volume of dis-
tribution. But after repeated high doses, the drug is
increasingly unbound and the pharmacokinetics not lin-
ear. Rohatagi et al. [35] concluded, in a study comparing
prednisolone and MP, that it was difficult to determine a
dose needed to obtain a desired concentration of pred-
nisolone in comparison with MP. However, the more
predictable pharmacokinetics of MP would suggest that
clearance is 40% less in obese subjects, needing a
lower dose. Therefore, Dunn et al. [36] advise that MP
should be administered on the basis of ideal body
weight rather than actual body weight. When starting
doses are calculated to actual body weight, should we
keep changing the dose to varying body weights?
Weight gain is a common effect of high-dose predniso-
lone. Continuing weight-based adjustments are not
practical because the fat content of the body composi-
tion is likely to continue fluctuating. But there is evi-
dence that lean body mass (LBM) does not fluctuate, at
least peripherally [37]. Formulae for LBM use gender,
height and weight as variables. The LBM is defined as
the weight of the body without the fat content.
Universally accepted formulae for this are unaffected by
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race and ethnicity. The LBM for men ¼ [0.32810weight
(in kg)] þ [0.33929height (in cm)]  29.5336; and for
women ¼ [0.29569weight (in kg)] þ [0.41813height
(in cm)]  43.2933 [38]. In our centre, we decided that
using LBM for tailoring prednisolone starting doses was
at least modestly evidence based rather than the one
size fits all of 40–60 mg daily.
Prednisolone tapering
If the initial dose of prednisolone represents the remis-
sion induction plan, the subsequent taper forms the plan
to maintain remission. To begin with, we looked at the
design of the prednisolone regimens of several clinical
trials (Fig. 1a) and plotted the mean and 95% CIs
(Fig. 1b). From the clinical trials, we selected the pred-
nisolone regimen that was used without another steroid-
sparing agent or i.v. MP. Next, we overlaid the relapse
rates from these clinical trials to give us an idea of the
efficacy of the regimens. Fig. 2a highlights the predniso-
lone regimen of the control arm from Mazlumzadeh
et al. [18]. Of the 13 patients treated with this regimen,
12 suffered relapses (92% relapse rate). The relapse
rate was calculated to be 190/100 person-years. Stone
et al. [12] had four arms in their trial; two of them were
placebo arms and one of those arms used a 52-week
prednisolone taper (Fig. 2b) [12]. Of the 51 patients
FIG. 1 Prednisolone regimens in clinical trials
(a) Prednisolone reduction regimens from 10 individual clinical trials. (b) Mean and 95% CIs of the prednisolone dose
from 10 clinical trials.
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enrolled in that arm, 42 relapsed (82% relapse rate). In
between those two extremes fall the control arm regi-
mens of Jover et al. [27] (15/18 individuals relapsed),
Seror et al. [33] (26/35 individuals relapsed), Villiger et al.
[39] (8/10 relapsed) and Langford et al. [29] (14/21
relapsed).
These data make it apparent that prednisolone regi-
mens from clinical trials cannot be used for routine clini-
cal practice because they have an impractically high
relapse rate. They are usually designed to demonstrate
treatment effect of the experimental drug. Therfore, is
there anything we can learn from them? Clinical trials
have multiple stake-holders, and the authors represent
the leaders in their fields. The agreed regimens for the
above clinical trials represent the distillation of the
efforts of several academic clinicians. Although the high
relapse rates make them ineffective for clinical use, they
do give us an idea of how prednisolone might be ta-
pered over time. Having plotted the mean and CIs
(Fig. 1b), we tested statistical models that gave the best
statistical fit (Table 1). The best information that we
could derive from the 10 regimens was that, in the view
of the experts, the reduction should be logarithmic.
One of the justifications for giving a larger than neces-
sary initial dose of prednisolone is that it might result in
longer remission maintenance. We tested this
FIG. 2 Relapse rates in two clinical trials superimposed on regimens from 10 clinical trials
(a) Hatched area highlights the regimen used by Mazlumzadeh et al. [18] in the placebo arm of the trial. This regimen
had a 92% relapse rate. (b) Hatched area highlights the regimen used by Stone et al. [12] in the 52-week placebo
arm of the trial. This regimen had 82% relapse rate.
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hypothesis indirectly by looking at the relapse rates and
the cumulative doses of prednisolone used in the above
clinical trials. Relapse rates have been reported for
prednisolone regimens used in six clinical trials (Fig. 3).
Statistical analysis of these data is not possible. But if
we divide the six regimens into two groups, those last-
ing for <6 months or those lasting >6 months, then visu-
ally the relapse rate appears to be an inverse function of
the cumulative prednisolone dose.
If our goal is drug-free sustained relapse, then prag-
matic cohort studies give us some idea of what the
stepping stones for prednisolone taper could be. Similar
to the starting dose, it seems that the presence of
extra-cranial disease does not affect the decision of the
clinician about prednisolone dosing. Muratore et al. [40]
published their experience in 332 patients (212 with cra-
nial GCA and 120 with extra-cranial involvement). The
mean daily dose of prednisolone was the same for both
groups [40]. This study also helps us to make the point
that clinical regimens produce lower relapse rates com-
pared with clinical trials. The relapse rates were 49/100
and 30/100 person-years in patients with extra-cranial
disease and cranial GCA, respectively. We may not re-
quire statistics to demonstrate that these numbers are
probably superior to the only clinical trial (Mazlumzadeh
et al. [18]), which reported a relapse rate of 190/100 per-
son-years in the control arm. Ly et al. [41] reported out-
comes in 395 patients in an inception cohort. The mean
(S.D.) daily dose of prednisolone was 18.8 (6) mg at
3 months and 7.4 (3.9) mg at 12 months. Likewise, the
12 month mean prednisolone dose was reported to be
7.38 mg by Kyle and Hazleman [42] and 6.6 mg by
Myklebust and Gran [43]. The aim to reach 20 mg by the
end of 3 months and 7 mg by the end of 12 months would
therefore seem reasonable. There are further clues to the
amount of prednisolone use necessary in the first year.
Chandran et al. [44] published 60 years of Mayo Clinic ex-
perience but divided their cohort into two 30-year groups
because of changes in practice. One hundred and
eighty-four patients treated between 1980 and 2009
needed a mean (S.D.) of 6.2 (2.7) g prednisolone in the
first year [44]. One hundred and fifty-seven patients
treated in Regio Emilia needed 7.1 (2.5) g mean (S.D.)
prednisolone in the first year [45]. When compared with
the cumulative dose achieved from the clinical trial regi-
mens (Fig. 3), these data from cohort studies inform us
that far more prednisolone is necessary in clinical
practice.
Duration of treatment
Autoimmune rheumatic diseases are not known for their
ability to be cured. But long-term remission is a real possi-
bility for almost all of them now. However, drug-free sus-
tained remission is possible in very few conditions. We
think GCA is one of them. From the original description,
Hutchinson remarked, ‘The old gentleman lived, I believe,
several years after this without any other manifestation of
arterial disease’ [2]. Robertson remarked, in 1947, ‘The
disease often lasts up to a year; it seems to be self-
TABLE 1 The equations of the statistical models for reduc-
tion of prednisolone and the coefficient of determination
Model Equation R2
Exponential y ¼ 16.475e0.005x 0.81
Linear y ¼ 0.0358x þ 19.112 0.45
Logarithmic y ¼ 10.24ln(x) þ 63.441 0.87
Polynomial y ¼ 0.0002x2  0.1525x þ 32.744 0.77
FIG. 3 Cumulative prednisolone dose (in grams) for six different prednisolone regimens and reported relapse rates in
percentages
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limiting and is rarely fatal’ [46] This was an opinion shared
by a number of early academics who had the opportu-
nity to observe the natural history of the disease. Thus,
is there a need to continue treating GCA beyond the
first year, or at all? Early on, it is imperative to treat
the urgent risk of ischaemic vascular complications.
There is evidence that GCA might continue to smoulder
in the larger vessels [47]. There is need to treat this
subclinical disease to avoid long-term vascular compli-
cations. Prednisolone at a dose of <7 mg daily (having
aimed for this in the first year) also starts functioning as
a glucocorticoid supplement.
The data for discontinuation of prednisolone is reason-
ably consistent. Koorey et al. [48] from Australia and
Proven et al. [31] from Minnesota, USA have both
reported 22 months to discontinuation of prednisolone in
35 and 87 patients, respectively. The French experience
concurs with this data. Ly et al. [41] reported that the
mean time to discontinuation for 395 patients was
26 months. In other cohorts, Fernandez-Herlihy et al. [49]
(n¼29), Andersson et al. [50] (n¼90) and Delecoeuillerie
et al. [51] (n¼78) reported the time to discontinuation as
6 years, 5.8 years and 31 months, respectively [49–51].
There is a wide spread in this data, but three studies
from different parts of the world came remarkably close
to the 2 year mark for discontinuation of prednisolone. It
would also be reasonable to surmise that if we reached
7 mg daily at the end of the first year, we could consider
discontinuation at the end of the second year.
There are some data that guide us to the overall
cumulative dose of prednisolone necessary to achieve
discontinuation. Proven et al. [31] from the USA used a
median cumulative dose of 6.5 g. Restuccia et al. [45]
from Italy used twice as much, at a mean dose of
12.1 g. Chandran et al. [44] did not report on cumulative
steroid use to discontinuation, but by the end of the
second year they had used a mean of 8.4 g of predniso-
lone. It is interesting that Chandran et al. [44] and
Proven et al. [31] have published from the same centre
but at different time points. The second paper com-
ments about the need to use higher doses of predniso-
lone to achieve the same results, but they cannot
explain the reasons for this change. The true dose to
achieve discontinuation is probably between 6.5 and
12 g.
The Norwich regimen
Using the information from the data discussed so far,
we ended up with an evidence base to formulate a
regimen.
. The starting dose needed to be between 20 and 60 mg
daily but should be tailored to the individual. LBM was a
very reasonable measurement to base the dose on.
. The taper should be logarithmic rather than linear. We
should aim to reach 20 mg daily by the end of 3
months and 7 mg daily by the end of 12 months.
. The cumulative dose of prednisolone in the first year
should be 6–7 g.
. The length of prednisolone treatment should be 2
years, and the cumulative dose of prednisolone to dis-
continuation may be 6–12 g.
Using the above information, we created the following
regimen:
. Starting prednisolone dose of 1 mg/kg/day of LBM,
thus achieving a tailored regimen.
. The taper was calculated as dose ¼
LBM(1log(100)W), where W is the number of weeks of
being on prednisolone. We used 100 as the base for
ease of calculation and to ensure that the dose of pred-
nisolone reduces to 0 mg at 100 weeks.
. Change in dose was made every 4 weeks only. In 25
steps, the regimen would be finished.
. The prednisolone dose was rounded to the nearest 5
mg for doses >20 mg daily.
. All patients receive 164.64 mg/kg LBM over the 100
weeks.
. Each individual receives a printed copy of the regimen
at diagnosis so that dose changes do not need medical
supervision (Supplementary material, available at
Rheumatology Advances in Practice online).
. Patients have open access to medical advice and ur-
gent medical appointments supported so that a relapse
can be diagnosed objectively in secondary care.
GCA is more common in women, and according to
the Office of National Statistics, UK, the average UK
woman is 161.2 cm tall and weighs 70.2 kg. Using our
regimen:
. The start dose would be 45 mg daily.
. At 12 weeks, the regimen would reach 21 mg daily, and
at 52 weeks the regimen would reach 6 mg daily.
. The cumulative prednisolone dose at the end of 1 year
would be 6.5 g.
. At 100 weeks, the prednisolone would be discontinued
after a cumulative dose of 7.4 g.
Using the data from a long-term epidemiological study
in Norfolk [52], we know that at the extremes of the
95% CI, a heavy Norfolk man is 186.3 cm tall and
weighs 114 kg, and a light Norfolk woman is 149.9 cm
tall and weighs 45.7 kg. Using these data, their prednis-
olone dosing regimen is as in Fig. 4a. These data are for
adults rather than the elderly, where the difference be-
tween the extremes may be less.
Summary
We have formulated a prednisolone regimen that has
become the recommended treatment for patients with
GCA in our NHS Trust. This paper proposes that using a
regimen based on LBM is preferable to one based on
actual body weight, although this needs further valida-
tion. The Norwich regimen has been formulated using
data from a wide variety of sources after an extensive
literature review. Input was received from all the rheu-
matology consultants and an ophthalmologist to sense-
check the statistical model. The regimen allows us to
tailor the dose of prednisolone for individual patients
and allows patients the autonomy of knowing when to
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change the dose and what to change it to. The Norwich
regimen therefore reduces the dependence that patients
have on clinicians and, conversely, the need for clini-
cians to supervise every dose reduction. This reduces
the need for hospital and primary care appointments.
This does not mean that patients should not continue to
be followed up to monitor disease and drug toxicity. We
continue to see patients periodically to monitor their
blood pressure, glycosylated haemoglobin and the
symptoms of relapse until the patients successfully
come off prednisolone. During this time, our patients
also continue to have open access to our service for as-
sessment of suspected relapse and side effects of pred-
nisolone. We anticipate that the Norwich regimen will
reduce the risk of relapses significantly, the outcomes of
which will be published in the coming years. If the out-
comes are favourable, this regimen could become the
benchmark against which other regimens could be
tested in clinical trials.
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